Vedanta Biosciences key facts
- Developer of orally delivered defined bacterial consortia designed to treat inflammatory and infectious diseases.
- It has raised $366.1M across 4 recorded rounds; the latest was Later Stage VC ($118.5M) in Mar 2023.
- Notable investors include Korea Investment Partners, Gates Foundation, Salica Investments, Johnson & Johnson Innovation - JLABS, Shinhan Capital — 38 tracked in total.
- Vedanta Biosciences has filed 7 Form Ds with the SEC since 2019, most recently Aug 2024 ($118.5M sold to 25 investors).
- Status: Privately Held (backing).
Who backs Vedanta Biosciences
38+- ·The complete investor list: 38 names
- ·Watch Vedanta Biosciences: the Monday email on marks, rounds and moves
Vedanta Biosciences funding rounds
4 roundsHow much has Vedanta Biosciences raised?
Vedanta Biosciences has raised $366 million across 4 recorded rounds since 2018. The largest was an $8 million early-stage round in Sep 2019; the most recent was an $119 million later-stage round in Mar 2023.
Vedanta Biosciences has filed 7 Form Ds with the SEC since 2019, most recently in Aug 2024 ($119 million sold to 25 investors).
Vedanta Biosciences investors
38 investors are on record for Vedanta Biosciences, including Korea Investment Partners, Gates Foundation, Salica Investments and Johnson & Johnson Innovation - JLABS. By type, the record holds 5 hedge funds and 5 venture capital firms. The later-stage round in Mar 2023 drew 25 investors.
About Vedanta Biosciences
Developer of orally delivered defined bacterial consortia designed to treat inflammatory and infectious diseases. The company's platform includes libraries of bacteria derived from the human microbiome, vast datasets from human interventional studies, proprietary capabilities in consortium design, and CGMP manufacturing through commercial launch, leading to the development of a potential new category of oral therapies based on defined consortia of bacteria isolated from the human microbiome and grown from pure clonal cell banks, enabling physicians to access oral therapies to treat autoimmune and inflammatory diseases efficiently.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2010
- Employees
- 136
- Website
- vedantabio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Vedanta Biosciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.